NRT & Prop 65
This article was originally published in The Tan Sheet
Executive Summary
California Supreme Court on Oct. 23 grants nicotine replacement therapy makers' petition to review appellate ruling finding Prop 65 warning is not federally preempted. FDA filed letter brief in support of manufacturers, saying Prop 65 warning language has been deemed unacceptable by the agency (1"The Tan Sheet" Sept. 23, 2002, p. 15)...
You may also be interested in...
Nicotine Replacement Therapy Prop 65 Warning Unfounded, FDA Tells Court
A California appellate court's ruling that a Prop 65 warning for nicotine replacement therapies is not federally preempted would require product manufacturers to use warning language FDA has determined lacks scientific support, the agency says
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.